Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.


TSX:SVA - Post by User

Comment by MoneyMouthon Jul 30, 2021 2:20am
97 Views
Post# 33630832

RE:RE:RE:RE:wannabe

RE:RE:RE:RE:wannabe
If these collaborations have been going on for years, then why was there a press release about it this year?? Oh yeah! Its because these are new collaborations. The latest MD&A was the first to talk about successful collaborations with pharma partners since atleast 2017.

When liquitity comes, those 100 million shares won't know when to sell and will probably end up missing the boat. It won't take much volume to move the share price up and down. If I recall correctly, back in january, the 7 trading days after the halt and big news release saw 30 million in volume. And the price went from $1.20, to $2.87, then back to $1.65. In one week. And yes, from $1.65 the financing was at a discount, but don't be dramatic and act like they robbed you from selling at $2.87. You had basically a 2 hour window to sell up there and you missed it. It was going to come back down quick no matter what.

The shareprice is going down because people are getting impatient, its also a pretty easy stock to play when there is no news. Buy at 1.20, sell at 1.60. Same pattern all year. Once we get close to $1.20, we'll probably bounce off of support and be on our way back up for a nice little run, and then if news is timed right, bon voyage!
<< Previous
Bullboard Posts
Next >>